ALPHAEON Corporation has expanded its partnership with Geneva-based TEOXANE Laboratories. Under terms of the agreement, TEOXANE will become the exclusive licensor and distributor of ALPHAEON’s neuromodulator, EVOSYAL, across the European Union, Central Europe, Russia and South Africa. The expanded partnership also provides TEOXANE with a right of first refusal to distribute all other ALPHAEON products and services that are brought to the European market.
ALPHAEON and TEOXANE began their partnership in August 2013, when ALPHAEON acquired an exclusive U.S. license to market the full line of TEOXANE’s cosmeceuticals and hyaluronic acid-based wrinkle-fillers.
"We are delighted to have expanded our partnership with TEOXANE,” said ALPHAEON Chief Executive Officer Robert E. Grant. “TEOXANE’s established direct and indirect sales channel will create market access for EVOSYAL across Europe.”
